


## **Supplementary Materials:**



Supplementary Figure 1. IFN- $\gamma$  synthesis by NK cells. Mice were injected with vehicle or α-GalCer. Twenty four hrs later, splenocytes were prepared, cultured with Golgi Plug<sup>TM</sup> for 6 h in the presence or absence of PMA plus ionomycin (IONO) and stained with anti-CD3-PerCP and anti-NK1.1-PE followed by anti-IFN- $\gamma$ -FITC (line) or FITC-labeled isotype control (shaded) mAb. Intracellular IFN- $\gamma$  expression by NK1.1<sup>high</sup>CD3<sup>-</sup> cells was evaluated. No IFN- $\gamma$  staining was obtained over the isotype control from NK cells in vehicle treated mice, whereas specific staining was obtained for α-GalCerinjected mice, as well as for spleen cells from vehicle-injected mice treated with PMA+IONO.



Supplementary Figure 2. Determination of B16 tumor lung metastases. B6 mice were injected with  $\alpha$ -GalCer or vehicle and one month later these animals were challenged i.v. with  $3x10^5$  B16 melanoma cells. The mice were also treated with  $\alpha$ -GalCer (5 µg/injection) or vehicle at 0, 4 and 8 days after the tumor challenge. A representative lung from each group is shown. Data are representative of 3 experiments with a total of at least 18 mice per group. Data are presented in a graphical format in Figure 4A.



Supplementary Figure 3. Anergy induction is independent of IFN- $\gamma$ . IFN- $\gamma$ -deficient mice were injected with vehicle or  $\alpha$ -GalCer (5 µg, i.p.), re-injected with vehicle or  $\alpha$ -GalCer 1 month later, sacrificed 3 days later, and the prevalence of NKT cells in the spleen was evaluated by flow cytometry. Representative data from 3 animals are shown. Data indicate that NKT cells from IFN- $\gamma$ -deficient mice that were injected 1 month earlier with  $\alpha$ -GalCer are refractory to  $\alpha$ -GalCer-induced expansion.

## **Supplementary Table 1.**

 $\alpha$ -GalCer can prevent EAE in mice injected one month earlier with a single dose of  $\alpha$ -GalCer.

Pretreatment	Treatment	Number of	Disease	Mean onset of	Mean	Mean
		mice	Frequency	disease (days)	maximum	Cumulative
					score	score
Vehicle	Vehicle	16	100%	12±0	4.18±0.18	103±3.7
Vehicle	α-GalCer	10	30%	16.4±0.24	0.5±0.16	7.4±3.8*
α-GalCer	Vehicle	15	100%	12.4±0.28	4.6±0.27	113.6±6.3
α-GalCer	α-GalCer	15	60%	15.5±0.5	1.13±0.19	23.3±5.4*

B6 mice were injected with vehicle or  $\alpha$ -GalCer. One month later, EAE was induced as described in the Methods and animals were treated with  $\alpha$ -GalCer or vehicle. Data shown represents mean values  $\pm$  SE. A graphical presentation of the data is shown in Figure 4B.

<sup>\*,</sup> p < 0.0001 as compared with vehicle-treated group.